DermTech
DermTech Revenues Nearly Quadruple in Q2
The company attributed the revenue spike to higher billable sample volume and improved average selling price for its skin cancer assays.
DermTech Q1 Revenues up 62 Percent
The firm processed approximately 9,400 billable samples in Q1, a 62 percent increase compared to approximately 5,800 samples in Q1 of 2020.
BTIG Initiates Coverage of DermTech With Buy Rating
The investment bank said DermTech's pigmented lesion assay for the early detection of melanoma is well positioned in an estimated $3 billion-plus market.
DermTech Q4 Revenues Up 31 Percent
For the three months ended Dec. 31, 2020, the La Jolla, California-based firm posted $2.1 million in revenues, up from $1.6 million in Q4 2019.
DermTech Enters Agreement With Blue Cross Blue Shield of Texas for Skin Cancer Assay
DermTech said its gene expression-based Pigmented Lesion Assay for the early detection of melanoma is now available as an in-network option for BCBSTX members.